论文部分内容阅读
目的观察两种雾化吸入方案在慢性支气管炎急性发作期的祛痰效果。方法将慢性支气管炎急性发作期无明显呼吸困难而咳嗽、咯痰明显的患者40例随机分成A组和B组各20例,2组在给予常规处理的基础上加超声雾化吸入,A组药物为地塞米松+糜蛋白酶+生理盐水,B组药物为氨溴索+生理盐水。比较2组临床疗效及不良反应发生情况。结果 A组不良反应发生率为20%高于B组的5%,B组总有效率为95%高于A组的80%,差异有统计学意义(P<0.05)。结论与地塞米松+糜蛋白酶相比,氨溴索雾化吸入对慢性支气管炎急性发作期的祛痰治疗是一种更好的选择。
Objective To observe the expectorant effect of two kinds of inhalation on acute exacerbation of chronic bronchitis. Methods Forty patients with chronic bronchitis without acute dyspnea and coughing and obvious expectoration were randomly divided into group A and group B (n = 20 in each group). The two groups were given routine inhalation of aerosol inhalation. Group A Drug dexamethasone + chymotrypsin + saline, B group drug ambroxol + saline. The clinical efficacy and adverse reactions of the two groups were compared. Results The incidence of adverse reactions in group A was 20% higher than that in group B, and the total effective rate in group B was 95% higher than that in group A (P <0.05). Conclusions Compared with dexamethasone + chymotrypsin, inhalation of ambroxol is a better choice for expectorant treatment of acute exacerbation of chronic bronchitis.